|Bid||38.33 x 2200|
|Ask||41.25 x 800|
|Day's Range||37.85 - 38.44|
|52 Week Range||35.10 - 45.09|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.73|
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Levi & Korsinsky announces it has commenced an investigation of Dycom Industries, Inc. (“Dycom” or “the Company”) (DY) concerning possible violations of federal securities laws. On August 13, 2018, Dycom announced disappointing results for the quarter ended July 28, 2018, and announced it would revise its financial guidance for fiscal 2019.
MARLBOROUGH, Mass., Aug. 16, 2018 /PRNewswire/ -- Hologic, Inc. (HOLX) announced today the U.S. launch of its new Fluent™ fluid management system, featuring innovations designed to provide operating room (OR) staff more simplified and effective fluid management for hysteroscopic procedures. "Fluid management plays a vital role in gynecological procedures, yet there have been few advances in the technology," said Edward Evantash, M.D., Medical Director and Vice President of Global Medical Affairs, Hologic. "The Fluent system is changing the game in fluid management.
Cynosure is the first medical aesthetic manufacturer offering enhanced patient experiences powered by Nitronox™ analgesia systems MARLBOROUGH, Mass. , Aug. 15, 2018 /PRNewswire/ -- Hologic, Inc. (Nasdaq: ...
Investors can rummage through the cheapie bin, looking for stocks with ultralow price-earnings ratios. But buying so-called deep value stocks isn't for the faint of heart: Their shares tend to be inexpensive because of a downturn in their business, and they may not rebound soon. Yet bargain hunters aren't entirely out of luck. Banks and other financial firms, for instance, trade at an average 36% discount to Standard & Poor's 500-stock index, based on the stocks' book value (assets minus liabilities), according to Bank of America Merrill Lynch. Some media companies also look inexpensive, along with technology firms that aren't as pricey as the stars of the tech world but still have strong prospects. The following seven stocks are bargains you can bet on for the long term. Our picks are profitable and leaders in their fields, but their shares trade at reasonable prices because of pressures in their industry or company-specific challenges. Eventually, we think those issues will subside. And for now, investors can buy these stocks at an attractive discount to the broad market or to industry averages. That should help set up strong returns, even if the stocks' prices rise only enough to get back to long-term average valuations. SEE ALSO: The 10 Best Stocks for GOP Tax Reform
NEW YORK, Aug. 14, 2018-- Levi & Korsinsky announces it has commenced an investigation of Hologic, Inc. concerning possible violations of federal securities laws. Hologic is the parent company of Cynosure, ...
Stocks that moved substantially or traded heavily Monday: VF Corp., down $3.47 to $92.82 The clothing company said it will make its denim business a separate company and focus on activewear and outdoor ...
Shares of Hologic Inc. (holx) fell 2.9% in premarket trade Monday, after the company said its Cynosure division will suspend marketing and distribution of its Vitalia TempSure device for heating of vaginal tissue, while it considers the Food and Drug Administration's concerns over "vaginal rejuvenation" procedures using energy-based devices. Cynosure received a letter from the FDA relating to its MonaLisa Touch laser, but although the letter didn't mention Vitalia, has elected to consider the concerns and is asking customers to return purchased devices.
In the fiscal third quarter, Hologic (HOLX) reported revenues of ~$91.7 million for its Medical Aesthetics segment. This is a YoY (year-over-year) decline of 18.0% on a constant currency basis. However, the business reported a sequential rise in revenues in the fiscal third quarter.
In the fiscal third quarter, Hologic (HOLX) reported revenues of ~$107.7 million for its GYN Surgical segment. This is a YoY (year-over-year) rise of 0.3% on a constant currency basis. Hologic expects its GYN Surgical business to witness significant improvement in the fiscal fourth quarter.
In the fiscal third quarter, Hologic (HOLX) reported revenues of ~$294.3 million for its Diagnostics segment. This represents a YoY (year-over-year) increase of 2.3% on a constant currency basis.
Hologic’s (HOLX) global Breast Health segment derives a significant portion of its revenues from new products and services, which complement the company’s Genius 3D mammography platform. This acquisition has added innovative products and solutions to Hologic’s portfolio. Faxitron Bioptic’s distribution efforts focus on pathologists and breast surgeons, which are also targeted by Hologic’s Breast Health team for mammography systems.
In its fiscal third-quarter conference call, Hologic (HOLX) narrowed the projected range of its fiscal 2018 EPS from $2.22–$2.27 to $2.24–$2.26. Considering the midpoint of the updated EPS guidance range, the company expects YoY (year-over-year) EPS growth of ~10.8% for fiscal 2018.
During its fiscal third quarter conference call, Hologic (HOLX) raised its fiscal 2018 non-GAAP revenue guidance from $3.18 billion–$3.21 billion to ~$3.21 billion–$3.22 billion. So, its YoY (year-over-year) reported revenue growth rate for fiscal 2018 is expected to be 4.8%–5.3%, higher than the previously projected range of 4.0%–4.9%.
In the fiscal third quarter, Hologic reported non-GAAP EPS of ~$0.58, which was a YoY rise of 16.0%. Hologic surpassed its revenue and EPS guidance for the fiscal third quarter. Hologic’s Diagnostics business posted a recovery compared to the fiscal second quarter, and its Surgical business has posted gradual improvement since the fiscal first quarter.
MARLBOROUGH, Mass. , Aug. 2, 2018 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the Canaccord Genuity 38 th Annual Growth Conference in New York, NY on Wednesday, ...
Hologic stock toppled below a buy point Wednesday as investors digested a packed quarter that included the exit of a key executive to Agilent and lower-than-expected quarterly guidance.
System's Latest Assay Increases Lab Efficiency and Flexibility With Highly Sensitive and Specific Detection MARLBOROUGH, Mass. , Aug. 2, 2018 /PRNewswire/ -- Hologic, Inc. (Nasdaq: HOLX) announced today ...
Shares of Hologic Inc. (holx) rose 2% late Tuesday after the medical technology company reported better-than-expected fiscal third-quarter earnings and sales. Hologic said it earned $113 million, or 41 cents a share, in the quarter, compared with $60 million, or 21 cents a share, a year ago. Hologic also raised its revenue and EPS guidance for fiscal 2018, saying it expect sales between $3.205 and $3.22 billion for the year, compared with a previous guidance of sales between $3.18 billion and $3.21 billion, and called for adjusted EPS between $2.24 and $2.26 for the year, from a previous guidance of an adjusted EPS between $2.22 and $2.27.
On a per-share basis, the Marlborough, Massachusetts-based company said it had profit of 41 cents. Earnings, adjusted for one-time gains and costs, were 58 cents per share. The results topped Wall Street ...
Yahoo Finance's Jared Blikre joins Seana Smith from the floor of the New York Stock Exchange to discuss the latest market moves a day after the 10-year yield breaches 3.0% and the yield curve widened.
Hologic CEO Steve MacMillan on the technological innovations in women's health, international growth, the potential impact of tariffs, acquisitions and efforts in Congress to repeal the medical device tax.